Bayer & Evotec Forge Partnership to Advance Precision Cardiology

The partnership sets its sights on developing innovative precision treatments to address the pressing medical needs within cardiovascular health.

Germany-based two pharmaceutical giants, Bayer and Evotechave have joined forces to develop innovative precision treatments for cardiovascular diseases (CVDs).

The partnership seeks to tackle the pervasive challenges of CVDs and address the pressing medical needs within cardiovascular health.

Further, the collaboration will identify and validate novel targets for treating cardiovascular diseases. 

Leveraging Evotec's expertise in disease modeling utilizing human induced pluripotent stem cells (iPSCs), both companies aim to build a robust portfolio of precision cardiology therapeutics. 

Sharing insights, Juergen Eckhardt, MD, head of business development & licensing, Pharmaceuticals Division, Bayer, said, "This development takes our long-standing collaboration with Evotec to a new level." Eckhardt emphasized, "We remain focused on developing innovative therapies for patients in need and to tackle the high burden of cardiovascular disease."

According to Dr Christian Rommel, head of R&D, Bayer’s Pharmaceuticals Division, the collaboration will leverage Evotec's industrialized iPSC-based disease modeling platform and Bayer’s leadership in cardiology.  “This complements our focus on disease areas where we can truly improve the standard of care by delivering superior therapeutic solutions to patients in need,” he added.

Shared Responsibilities & Future Prospects

Both Bayer and Evotec will share responsibilities during the pre-clinical development phase of potential clinical candidates. Bayer will take charge of subsequent clinical development and commercialization.

Commenting on the same, Dr Cord Dohrmann, chief scientific officer of Evotec, shed light on the approach adopted by the partnership. He elucidated, "To move the treatment paradigm beyond disease management, it is important to advance our understanding of the disease-relevant molecular mechanisms underlying cardiovascular diseases." 

Financial Terms & Outlook

While the collaboration's financial terms were not disclosed, Bayer's focus on advancing precision cardiology is evident. With a robust portfolio of innovative treatments in cardiovascular diseases, Bayer aims to address the high unmet medical needs in this critical healthcare domain.

Recently, Bayer and Google Cloud have joined hands to advance the integration of AI into healthcare imaging processes. 

This partnership seeks to enhance the capabilities of radiologists and improve patient outcomes by developing innovative AI-powered applications.

In the collaboration, Nelson Ambrogio, president of radiology at Bayer, said, "The need to efficiently and accurately uncover insights in healthcare imaging has never been greater." 

According to him, Bayer will continue to leverage its decades-long radiological research and innovation expertise to transform data into impactful insights that benefit patients.

Founded in 1863 in Barmen, Germany, Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition dedicated to improving lives and fostering sustainable development.